Amgen Stock Holds Near USD 403 as Cantor Fitzgerald Maintains Neutral Rating
On October 5, 2026, Amgen Inc. (ISIN US0311621009) saw its stock price reach USD 403.25 on the Nasdaq. Despite this, Cantor Fitzgerald maintained a Neutral rating for the company, setting a price target of USD 400, just USD 3.25 below the current market price. The firm's assessment cited commercial execution as a key factor while also highlighting positive clinical data in Sjogren's disease and revised expectations for Lp(a) following HORIZON results.
Amgen reported strong financial performance for the second quarter of 2026, with revenue hitting USD 10.05 billion, a 9.5 percent increase year-over-year. This growth contrasts with Cantor Fitzgerald's Neutral stance, underscoring the company's robust commercial base amid analyst concerns about competition and pipeline catalysts.
The market's consensus on Amgen's stock is mixed, with an average price target of USD 385.25, significantly lower than the current trading price. Analysts are divided, with one Strong Buy, eleven Buy, fifteen Hold, and three Sell ratings. As of October 5, 2026, Amgen's stock was trading at USD 403.25, up 0.05 percent on the session, with a market capitalization of USD 217.6 billion and a 52-week range of USD 288.00 to USD 447.03.